Episode 198 - October 2, 2026

Public biotech markets remain resilient, with the XBI index significantly outperforming broader healthcare and tech benchmarks despite recent volatility. Strategic partnerships define current industry momentum, highlighted by the Regeneron-Sanofi collaboration extension and AstraZeneca’s $2 billion equity investment in Summit Therapeutics to advance bispecific oncology assets. Clinical trial outcomes, such as Kodiak’s positive wet AMD data and Dyn Therapeutics’ DM1 results, underscore the sector’s high-stakes nature. Meanwhile, the obesity landscape continues to accelerate, as Eli Lilly’s retatritide and amylin combinations demonstrate substantial weight loss efficacy in diabetic populations. Gene therapy development faces ongoing challenges, evidenced by the mixed clinical results in Huntington’s disease, reinforcing the difficulty of translating molecular mechanisms into consistent patient outcomes. These developments reflect a broader trend of high-risk, high-reward innovation across ophthalmology, oncology, and metabolic disease.